DexCom Inc. (DXCM) — RQD Stock Rating Cockpit
DexCom Inc. (DXCM) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (60% profit margin, 22% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
Real cash coming in backs up reported profits (60% profit margin and healthy balance-sheet cushion).
Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.
Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.
2-of-3 JEV AI Jury Bullish on DXCM
21.6% ROIC with 60.1% gross margin and 3.57% FCF yield.
Altman-Z 7.14 and Piotroski 9/9 pass balance-sheet audit.
Put/Call 0.86x with 22/40 institutional & insider flow.
- ✓Strong cash generator (60% profit margin)—profits are backed by real money, not accounting tricks.
- ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
- !Broader market pullbacks can still drag down strong stocks in the short run.
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live DXCM Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
DXCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +15.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DXCM today. View full Setup Ledger →
DXCM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDShould I buy, hold, or sell DXCM stock right now?
DexCom Inc. (DXCM) currently earns a Roarable Rating of B (Buy — BUY) with 73/100 RQD Confidence. High-quality cash engine (60% profit margin, 22% return on capital) with steady institutional support.
What is DXCM's 12-month price target and RQD AI Jury consensus?
DXCM's 12-month base price target is $85.33 (range $65.54 to $100.69), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.